SCHEDULE: Goldman Sachs Discloses 5.2% Stake in Indivior PLC

Goldman Sachs Group and its affiliate have reported a 5.2% beneficial ownership stake in Indivior PLC, totaling over 6.5 million shares.

Summary

• The Goldman Sachs Group, Inc. and its subsidiary, Goldman Sachs & Co. LLC, have jointly filed an Amendment No. 2 to Schedule 13G.
• The filing reports beneficial ownership of 6,531,868.75 ordinary shares of Indivior PLC, representing 5.2% of the class.
• The shares have shared voting power of 6,531,833.75 and shared dispositive power of 6,531,868.75.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Indivior PLC.
• The event requiring this filing is dated September 30, 2025.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's operational performance or financial health. It is a neutral reporting of an investment stake.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Indivior PLC's future performance or operations.

Industry Context

This filing indicates a significant institutional investment by Goldman Sachs in Indivior PLC, a pharmaceutical company. Such disclosures are common for large financial institutions managing diverse portfolios and can signal market confidence or strategic positioning within the healthcare or pharmaceutical sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a major institutional investor like Goldman Sachs could be viewed positively, potentially signaling confidence in Indivior PLC's long-term prospects or valuation.

Key Dates

Keywords

Indivior PLC, Goldman Sachs, Beneficial Ownership, Schedule 13G, Institutional Investment, Ordinary Shares, SEC Filing